Alcohol Withdrawal Management Protocol

Overview & Epidemiology

Alcohol withdrawal syndrome is a potentially life-threatening condition that occurs when individuals with alcohol dependence abruptly reduce or cease alcohol consumption. Understanding its epidemiology and implementing evidence-based management protocols is essential for PMHNPs in both inpatient and outpatient settings.

Key Statistics

5% of US adults will experience alcohol withdrawal in their lifetime
1-4% mortality for untreated delirium tremens (DTs)
~15% mortality for untreated withdrawal seizures
<1% mortality when properly treated

Fixed-Schedule vs. Symptom-Triggered Treatment

Research demonstrates clear superiority of symptom-triggered protocols:

Fixed-schedule results in 2-3x more benzodiazepine use without improved outcomes
Symptom-triggered (CIWA-Ar ≥10) delivers 50% reduction in benzodiazepine dose, shorter treatment duration, and equivalent efficacy
CIWA-Ar-based protocols reduce oversedation while maintaining seizure prophylaxis

Pathophysiology

Alcohol withdrawal is fundamentally a disorder of neuroadaptation. Chronic alcohol exposure produces compensatory changes in central nervous system neurotransmission that become unmasked upon cessation.

GABA-A Receptor Dynamics

Alcohol is a potent GABA-A receptor agonist, enhancing inhibitory neurotransmission
Chronic use leads to receptor downregulation and reduced sensitivity
Abrupt cessation creates GABA deficiency relative to the adapted state
Result: neuronal hyperexcitability manifesting as the withdrawal syndrome

Withdrawal Timeline

Minor withdrawal: 6-24 hours after last drink
Seizures: 24-48 hours peak risk
Delirium Tremens: 48-72 hours peak, can persist 5-7 days

The Kindling Effect

Each withdrawal episode sensitizes the central nervous system, increasing the severity and seizure risk of subsequent withdrawals. This neurobiological phenomenon underscores the importance of:

Aggressive treatment of index withdrawal episodes
Early referral to medication-assisted treatment (MAT)
Patient education about cumulative risk

CIWA-Ar Assessment Tool

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the gold standard for quantifying withdrawal severity and guiding treatment decisions.

Domain	Score Range	Assessment Focus
Nausea/Vomiting	0-7	Severity of nausea, episodes of vomiting
Tremor	0-7	Arm/hand tremor at rest with arms extended
Diaphoresis	0-7	Visible sweating at rest, beads of sweat
Anxiety	0-7	Subjective anxiety, nervousness, apprehension
Agitation	0-7	Observable restlessness, inability to sit still
Perceptual Disturbances	0-7	Hallucinations, illusions, tactile disturbances
Headache/Fullness	0-7	Severity of headache, head pressure
Auditory Disturbances	0-7	Hypersensitivity to sound, auditory hallucinations
Visual Disturbances	0-7	Hypersensitivity to light, visual hallucinations
Orientation/Clouding	0-4	Time, place, person orientation; sensorium clarity

CIWA-Ar Scoring Thresholds

Maximum Score: 67 points

<8: Mild withdrawal — Monitor, minimal intervention
8-15: Moderate withdrawal — PRN medication indicated
15-20: Moderately severe — Scheduled medication, close monitoring
>20: Severe withdrawal — Consider ICU, phenobarbital

Risk Stratification

Appropriate level of care determination is critical for safe withdrawal management. Use the three-tier system below to guide disposition decisions.

🟢 Low Risk

Criteria:

CIWA <15
No prior seizures/DTs
No significant medical comorbidities

Management:

Ambulatory management
CIWA q4-8h
Lorazepam PRN

🟡 Moderate Risk

Criteria:

CIWA 15-24
Prior withdrawal episodes
Comorbid medical illness

Management:

Inpatient general floor
CIWA q1-4h
Scheduled benzodiazepines

🔴 High Risk

Criteria:

CIWA >25
Prior seizures or DTs
Severely ill/multicomorbid

Management:

ICU level care
CIWA q1h
IV benzodiazepines or phenobarbital

Strongest Predictors of DTs/Seizures

Risk Factors (Evidence-Based)

History of prior withdrawal seizure (RR 5.2)
History of prior delirium tremens
Age >40 years
Concurrent medical illness
CIWA >15 at presentation

Clinical Algorithm

The following stepwise approach guides clinical decision-making from initial assessment through discharge planning.

Suspected Alcohol Use Disorder

Patient presents with history of heavy alcohol use, last drink within past 72 hours

Obtain CIWA-Ar Score

Complete 10-item assessment

CIWA <8: Monitor only CIWA 8-15: PRN benzos + monitoring CIWA ≥15: Scheduled benzos + close monitoring CIWA ≥25: Consider ICU + phenobarbital

Reassess CIWA

Frequency determined by severity tier: q1h (severe), q1-4h (moderate), q4-8h (mild)

Refractory Symptoms?

If CIWA remains elevated despite adequate benzodiazepine dosing

Escalate to phenobarbital protocol

Resolution Criteria Met?

CIWA <8 sustained for 24 hours

Discharge planning with naltrexone/acamprosate counseling

Benzodiazepine Selection Guide

All benzodiazepines are effective for alcohol withdrawal through GABA-A agonism. Selection depends on patient characteristics, comorbidities, and clinical setting.

Drug	Half-life	Route	Clinical Notes	Best For
Lorazepam	10-20h	PO/IV/IM	No active metabolites; glucuronidation preserved in liver disease	Liver disease, outpatient, ICU
Diazepam	20-100h	PO/IV	Active metabolites create self-tapering effect; rapid onset	Healthy adults, severe withdrawal
Chlordiazepoxide	5-30h	PO	Long-acting, active metabolites, no IV formulation	Mild-moderate, outpatient
Oxazepam	5-15h	PO	No active metabolites; glucuronidation	Liver disease, elderly

Mechanism of Action

All benzodiazepines are GABA-A receptor allosteric modulators, substituting for alcohol at the receptor level. This substitution prevents neuronal hyperexcitability while the CNS gradually readapts to the absence of alcohol.

Dosing Protocols

Symptom-Triggered Protocol (Preferred)

Lorazepam: 1-2 mg PO/IV q1h PRN CIWA ≥8
OR Diazepam: 5-10 mg PO q1h PRN CIWA ≥8
Maximum: No fixed maximum — treat to effect
Monitoring: CIWA, HR, BP, RR, SpO₂

Scheduled Protocol (High-Risk Patients)

Lorazepam: 2 mg PO q6h × 4 doses, then 1 mg PO q6h × 8 doses
OR Chlordiazepoxide: 25-100 mg PO q6h tapering over 5-7 days
Add PRN component for breakthrough symptoms
Consider in patients with seizure history or prior DTs

Load-and-Taper Protocol

Diazepam: 10-20 mg PO q1-2h until CIWA <10
Then q6h × 24 hours
Then taper 25% per day
Useful for severe withdrawal requiring rapid control

Monitoring Parameters

Systematic monitoring ensures early detection of deterioration and guides treatment adjustments.

Assessment Frequency

CIWA-Ar: Per risk tier (q1h severe, q1-4h moderate, q4-8h mild)
Vital Signs: HR, BP, temperature, RR, SpO₂

Laboratory Monitoring

BMP (electrolytes, renal function)
Liver function tests
Magnesium, phosphate
Thiamine level (if available)

Ancillary Studies

EEG: If seizure occurs or suspected non-convulsive status

Critical Interventions

Thiamine 100-500 mg IV BEFORE glucose — Glucose administration before thiamine can precipitate acute Wernicke's encephalopathy

Magnesium sulfate 2g IV if Mg <1.8 mEq/L — Reduces seizure risk and cardiac irritability

Escalation Criteria

Recognizing when standard management is insufficient triggers implementation of phenobarbital protocol or ICU transfer.

Indications for ICU Transfer / Phenobarbital Protocol

CIWA >25 despite adequate benzodiazepine dosing
Seizure(s) occurring during withdrawal management
Delirium tremens developing (confusion + autonomic instability)
Requiring >40 mg lorazepam equivalent in 24 hours
Airway compromise or inability to protect airway
Hemodynamic instability (hypotension, arrhythmias)

Benzodiazepine-Refractory Withdrawal

When escalating benzodiazepine doses fail to control symptoms, consider:

Concurrent medical illness masking response
Pharmacokinetic issues (rapid metabolism, malabsorption)
True benzodiazepine resistance → phenobarbital indicated

Special Populations

Liver Disease

Preferred: Lorazepam or oxazepam
Avoid: Diazepam, chlordiazepoxide (active metabolites accumulate)
Glucuronidation preserved even with significant hepatic dysfunction

Elderly Patients

Reduced starting doses (typically 50% of adult dose)
Higher risk of falls, delirium, and respiratory depression
Prefer shorter-acting agents (lorazepam, oxazepam)
More frequent monitoring of mental status

Pregnancy

First-line: Lorazepam
Coordinate with obstetrics for fetal monitoring
Risk of neonatal abstinence syndrome (NAS) in newborn
Weigh risks of untreated withdrawal vs. medication exposure

Seizure History

Pre-treat with scheduled benzodiazepines regardless of initial CIWA score
Lower threshold for ICU admission
Consider prophylactic phenobarbital in severe cases

Concurrent Medical Illness

Lower threshold for ICU level of care
Watch for withdrawal symptoms masking underlying pathology
Enhanced monitoring for medication interactions

Phenobarbital Protocol

Phenobarbital offers a distinct mechanism of action and is increasingly recognized as a first-line option in severe withdrawal rather than a rescue therapy.

Dosing

Loading Dose: 10-15 mg/kg IV (maximum 1000 mg) at ≤50 mg/min
Maintenance: 30-120 mg PO/IV q8-12h

Advantages Over Benzodiazepines

Different mechanism: GABA-A allosteric modulator with additional glutamate antagonism
Long half-life provides self-tapering
Reduces need for mechanical ventilation in severe DTs
Not subject to same tolerance mechanisms as benzodiazepines

Safety Monitoring

Respiratory depression (most common serious adverse effect)
Excessive sedation
Blood levels (therapeutic 10-40 mcg/mL)

Adjunctive Ketamine (Limited Evidence)

0.3-0.5 mg/kg/h IV infusion for refractory delirium tremens when phenobarbital and benzodiazepines fail. Requires ICU monitoring. Evidence base is limited to case series and small observational studies.

Clinical Pearls

Essential wisdom for PMHNPs managing alcohol withdrawal.

1 "Treat the patient, not the score" — CIWA is a guide, not an absolute threshold. Clinical judgment always prevails.

2 "Give thiamine BEFORE glucose" — Glucose first can precipitate acute Wernicke's encephalopathy. Always replete thiamine first.

3 "Symptom-triggered > fixed schedule" — 50% less benzodiazepine, same outcomes. Less oversedation, shorter stays.

4 "The kindling effect is real" — Each withdrawal episode increases seizure risk. Prioritize long-term treatment engagement.

5 "Lorazepam in liver disease" — Safer than diazepam because glucuronidation is preserved even with significant hepatic dysfunction.

6 "Phenobarbital is not second-line, it's parallel" — Consider early in high-risk patients. Don't wait for benzodiazepine failure.

7 "Discharge with naltrexone/acamprosate" — Withdrawal management is the acute phase; MAT is the treatment. Bridge to recovery.

References

American Society of Addiction Medicine (ASAM). Clinical Practice Guideline on Alcohol Withdrawal Management. Journal of Addiction Medicine. 2020;14(3S):1-96.
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction. 1989;84(11):1353-1357.
Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews. 2010;(3):CD005063.
Saitz R. Introduction to alcohol withdrawal. Alcohol Health and Research World. 1998;22(1):5-12.
Lum E, Saeed Y, Hadi S, et al. Phenobarbital for alcohol withdrawal syndrome: A systematic review and meta-analysis. Pharmacotherapy. 2020;40(11):1142-1154.
Substance Abuse and Mental Health Services Administration (SAMHSA). TIP 45: Detoxification and Substance Abuse Treatment. DHHS Publication No. (SMA) 15-4131. Rockville, MD: SAMHSA; 2015.